Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs
Investigational and unapproved. Findings below describe what trials and reports have observed. Nothing here is an endorsement, a claim of safety or effectiveness, or a clinical recommendation.

Danuglipron

INVESTIGATIONAL

oral non-peptide small-molecule GLP-1 receptor agonist

5
graded findings
4
effect domains
Evidence spread
High evidence 0Moderate evidence 2Low evidence 0Very low evidence 3

Danuglipron is shown as an investigational or pipeline evidence record. Findings describe what studies and reports observed; they do not endorse use or establish personal suitability.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Danuglipron INVESTIGATIONAL
Pharmacology and mechanism Decrease
Very low evidence

Oral non-peptide GLP-1RA (PF-06882961, Pfizer). Phase 2b twice-daily data showed clinically meaningful weight loss in obesity; once-daily formulation met PK...

Pfizer press release, 14 April 2025; STAT/CNBC/BioPharma Dive coverage Source
Full findingOral non-peptide GLP-1RA (PF-06882961, Pfizer). Phase 2b twice-daily data showed clinically meaningful weight loss in obesity; once-daily formulation met PK objectives. Development DISCONTINUED for weight management on 14 April 2025 after a single asymptomatic participant experienced potential drug-induced liver injury that resolved on discontinuation; Pfizer stated overall liver-enzyme elevation frequency across the >1,400 participant database was in line with approved class agents.
PopulationPhase 2b: adults with obesity (with/without T2D); >1,400 participant total safety database
Fundingindustry - Pfizer (trial sponsor; inferred from registration trial)
Scope limitsMECHANISM: oral non-peptide small-molecule GLP-1R agonist. DISCONTINUED Apr 2025 - single case of potential DILI (asymptomatic, resolved) plus regulator input. Pfizer's SECOND oral GLP-1 dropped for hepatic concerns (see lotiglipron). Phase-2b magnitudes are press-reported.
Comparatorsplacebo
Danuglipron INVESTIGATIONAL
Pharmacology and mechanism Not directional
Very low evidence

Moderate hepatic metabolism / low intrinsic clearance in vitro; multiple phase I/II metabolites identified.

Jaiswal A et al. Comprehensive identification and characterization of in vitro and in viv... Source
PopulationIn vitro (human/rat liver microsomes, S9) and in vivo rat
Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)
Scope limitsanimal data; human relevance uncertain
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Danuglipron INVESTIGATIONAL
Safety signals Increase
Very low evidence

Drug-induced liver injury signal leading to program discontinuation.

Pfizer press release: Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron, ... Source
PopulationPfizer dose-optimisation program (post phase 2b); chronic weight management
Fundingindustry - Pfizer (trial sponsor; inferred from registration trial)
Scope limitsDiscontinuation driver. Single-case hepatotoxicity vs class-typical aggregate LFTs is the central tension (recorded neutrally, no verdict). Press-sourced.
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Danuglipron INVESTIGATIONAL
Gastrointestinal tolerability Increase
Moderate evidence

High GI adverse-event burden, dose-related, driving high discontinuation.

Buckeridge C et al. Efficacy and safety of danuglipron (PF-06882961) in adults with obesi... Source
PopulationPhase 2b N=628 (NCT04707313); 26/32 wk; placebo comparator
Fundingindustry - Pfizer
Scope limitsAuthors note discontinuation rates higher than anticipated across ALL groups including placebo. Most GI events mild.
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Danuglipron INVESTIGATIONAL
Weight change Decrease
Moderate evidence

Phase 2b: statistically significant, dose-dependent weight reduction vs placebo over 26/32 weeks.

Buckeridge C et al. Efficacy and safety of danuglipron (PF-06882961) in adults with obesi... Source
PopulationPhase 2b RCT (NCT04707313), N=628 randomised (536 danuglipron, 90 placebo), adults with obesity without diabetes; danuglipron BID; placebo comparator
Fundingindustry - Pfizer
Scope limitsDISCONTINUED: Pfizer halted danuglipron (chronic weight management) in April 2025 after a single asymptomatic case of drug-induced liver injury (resolved on discontinuation), despite class-typical aggregate LFT-elevation rates across >1400 participants. Only 39.3% completed treatment; ~38% discontinued due to AEs (high even vs placebo) — tolerability of BID dosing a concern.
Comparatorsplacebo